Secretory phospholipase A2: A marker of infection in febrile children presenting to a pediatric ED

American Journal of Emergency Medicine

Volumn 29, Issue 9, 2011, Pages 1163-1168

  Mansour, Karim M ^a   Kuypers, Frans A ^b   Wang, Tammy N ^a   Miller, Annabeth M ^b   Larkin, Sandra K ^b   Morris, Claudia R ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2; BIOLOGICAL MARKER; SECRETORY PHOSPHOLIPASE A2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD CELL COUNT; BLOOD CULTURE; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY WARD; ENZYME BLOOD LEVEL; FEMALE; FEVER; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEDIATRIC WARD; PREDICTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SCREENING TEST; SENSITIVITY AND SPECIFICITY; URBAN AREA; URINE CULTURE; VIRUS INFECTION; BLOOD; EMERGENCY HEALTH SERVICE; INFECTION; MICROBIOLOGY; NEWBORN; NONPARAMETRIC TEST;

ADOLESCENT; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EMERGENCY SERVICE, HOSPITAL; FEMALE; FEVER; HUMANS; INFANT; INFANT, NEWBORN; INFECTION; LEUKOCYTE COUNT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHOSPHOLIPASES A2, SECRETORY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; VIRUS DISEASES;

EID: 80855136399     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2010.06.024     Document Type: Article

References (31)

1. Kaplan S.L., Mason E.O. Jr., and Wald E.R. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine Pediatrics 113 2004 443 449
2. Whitney C.G., Farley M.M., and Hadler J. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 18 2003 1737 1746
3. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., and Ramirez M. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine Clin Microbiol Infect 14 9 2008 835 843
4. Lee G.M., and Harper M.B. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era Arch Pediatr Adolesc Med 152 7 1998 624 628
5. Bachur R., Perry H., and Harper M.B. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis Ann Emerg Med 33 2 1999 166 173
6. Shaw K.N., Gorelick M., McGowan K.L., Yakscoe N.M., and Schwartz J.S. Prevalence of urinary tract infection in febrile young children in the emergency department Pediatrics 102 2 1998 e16
7. Alpern E.R., Alessandrini E.A., Bell L.M., Shaw K.N., and McGowan K.L. Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome Pediatrics 106 3 2000 505 511
8. Hsiao A.L., and Baker M.D. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children Curr Opin Pediatr 17 1 2005 56 61
9. Bonsu B.K., Chb M., and Harper M.B. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? Ann Emerg Med 42 2 2003 216 225
10. Isaacman D.J., and Burke B.L. Utility of the serum C-reactive protein for detection of occult bacterial infection in children Arch Pediatr Adolesc Med 156 9 2002 905 909
11. Pulliam P.N., Attia M.W., and Cronan K.M. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection Pediatrics 108 6 2001 1275 1279
12. Gendrel D., and Bohuon C. Procalcitonin as a marker of bacterial infection Pediatr Infect Dis J 19 8 2000 679 687 [quiz 688]
13. Andreola B., Bressan S., Callegaro S., Liverani A., Plebani M., and Da Dalt L. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department Pediatr Infect Dis J 26 8 2007 672 677
14. Gendrel D. Use of procalcitonin at the pediatric emergency room Arch Pediatr 11 6 2004 582 584
15. van Rossum A.M., Wulkan R.W., and Oudesluys-Murphy A.M. Procalcitonin as an early marker of infection in neonates and children Lancet Infect Dis 4 10 2004 620 630
16. Fernandez Lopez A., Luaces Cubells C., Garcia Garcia J.J., and Fernandez Pou J. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker Pediatr Infect Dis J 22 10 2003 895 903
17. Galetto-Lacour A., Zamora S.A., and Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center Pediatrics 112 5 2003 1054 1060
18. Lorrot M., Moulin F., and Coste J. Procalcitonin in pediatric emergencies: comparison with C-reactive protein, interleukin-6 and interferon alpha in the differentiation between bacterial and viral infections Presse Med 29 3 2000 128 134
19. Maniaci V., Dauber A., Weiss S., Nylen E., Becker K.L., and Bachur R. Procalcitonin in young febrile infants for the detection of serious bacterial infections Pediatrics 122 4 2008 701 710
20. Gendrel D., and Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections Intensive Care Med 26 Suppl 2: 2000 S178 S181
21. Bachur R.G., and Harper M.B. Predictive model for serious bacterial infections among infants younger than 3 months of age Pediatrics 108 2 2001 311 316
22. Baraff L.J. Management of fever without source in infants and children Ann Emerg Med 36 6 2000 602 614
23. Pruzanski W., and Vadas P. Phospholipase A2-a mediator between proximal and distal effectors of inflammation Immunol Today 12 5 1991 143 146
24. Ballas S.K., Files B., and Luchtman-Jones L. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome Hemoglobin 30 2 2006 165 170
25. Rintala E.M., Aittoniemi J., Laine S., Nevalainen T.J., and Nikoskelainen J. Early identification of bacteremia by biochemical markers of systemic inflammation Scand J Clin Lab Invest 61 7 2001 523 530
26. Rintala E.M., and Nevalainen T.J. Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections Clin Infect Dis 17 5 1993 864 870
27. Partrick D.A., Moore E.E., Silliman C.C., Barnett C.C., and Kuypers F.A. Secretory phospholipase A2 activity correlates with postinjury multiple organ failure Crit Care Med 29 5 2001 989 993
28. Kuypers F.A., and Styles L.A. The role of secretory phospholipase A2 in acute chest syndrome Cell Mol Biol (Noisy-le-grand) 50 1 2004 87 94
29. Neidlinger N.A., Hirvela E.R., Skinner R.A., Larkin S.K., Harken A.H., and Kuypers F.A. Postinjury serum secretory phospholipase A2 correlates with hypoxemia and clinical status at 72 hours J Am Coll Surg 200 2 2005 173 178
30. Austin D.J., Kristinsson K.G., and Anderson R.M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance Proc Natl Acad Sci U S A 96 3 1999 1152 1156
31. DeAngelis C., Joffe A., Wilson M., and Willis E. Iatrogenic risks and financial costs of hospitalizing febrile infants Am J Dis Child 137 12 1983 1146 1149